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Abstract Eosinophilic myocarditis (EM) is a rare and
potentially fatal disease if left untreated. Because the dis-
ease can have a delayed presentation and can appear even
after 2 years, its underlying causes often remain unknown.
We report the case of a 63-year-old man with an atypical
clinical presentation of hypersensitive EM and significant
coronary artery disease, which was confirmed through
coronary angiography. The patient was treated with
hydrochlorothiazide (12.5 mg once daily for 2 years) and
budesonide/formoterol (160/4.5 lg once daily for 2 years).
Amoxicillin/clavulanic acid (1000/200 mg three times
daily for 2 days) and azithromycin (500 mg once daily for
2 days) were used to treat pneumonia, while ibuprofen
(600 mg three times daily for 2 days) was used to treat
pericarditis. Extremely high levels of eosinophils led to
clinical suspicion of non-acute coronary syndrome as the
cause of chest pain and myocardial necrosis. In addition,
early pulse doses of methylprednisolone (500 mg intra-
venously once daily) were administered. Complete clinical
recovery and a fast decrease in eosinophils and troponin
levels were observed after a few hours on the same day. No
signs of recurrent myocarditis were noticed after 3 days of
administering the same pulse doses of methylprednisolone,
which was then replaced by oral methylprednisolone
administered for the next 2 months (step-down regimen,
starting from 64 mg/day). Despite causality assessment
being difficult, prompt therapy must be given as soon as
possible to prevent fatal outcomes. Delayed corticosteroid
treatment, which is necessary regardless of the underlying
cause, can result in heart failure and death.
Key Points
Due to an atypical clinical presentation,
hypersensitivity eosinophilic myocarditis is rarely
clinically recognised and the cause of the disease
frequently remains unknown.
Prompt diagnosis of hypersensitivity eosinophilic
myocarditis and appropriate treatment with pulse
doses of corticosteroids are crucial, because it can
lead to a fatal outcome if left untreated.
Introduction
Eosinophilic myocarditis (EM) is a rare and potentially
fatal disease if left untreated. It is rarely recognised clini-
cally and is often first discovered during a post-mortem
examination [1]. There are numerous drugs that have been
involved in causing the hypersensitivity form of EM (an-
tibiotics, anticonvulsants and diuretics) but the cause of the
disease often remains unknown. The hypersensitivity form
may develop early during use of the causative drug or may
have a delayed presentation after as long as 2 years.
According to Gell and Coombs [2], drug hypersensitivity
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reactions with eosinophilic inflammation and T helper cell
type 2 (Th2) immune response (clinically maculopapular
eruptions and a reaction to drugs with eosinophilia and
systemic symptoms) present as a type IV reaction, which is
a delayed type of hypersensitivity reaction; EM is consid-
ered to be a delayed hypersensitivity reaction [2–4].
Signs and symptoms of hypersensitivity (skin rash,
fever, eosinophilia and malaise) and non-specific cardiac
findings (electrocardiographic changes, tachycardia or
elevated cardiac enzymes) suggest hypersensitivity
myocarditis [3].
In this case report we present an atypical clinical pre-
sentation of hypersensitivity eosinophilic myocarditis,
presenting mostly as a respiratory infection with flu-like
symptoms with an abnormally high eosinophil count.
Coronary angiography revealed significant pathomorpho-
logical changes.
Case Report
A 63-year-old man presented to the emergency department
with a history of flu-like symptoms, fever and malaise
followed by respiratory-dependent chest pain. The patient
had a 2-year history of arterial hypertension and chronic
bronchitis, which was treated with hydrochlorothiazide
(12.5 mg once daily for 2 years) and budesonide/for-
moterol (160/4.5 lg once daily for 2 years). There had
been no prior animal exposure. Physical examination
revealed reduced breathing sounds; there were no signs of
heart failure. Laboratory tests revealed leukocytosis
(leukocyte count of 16.3 9 109/L) with a slightly elevated
eosinophil count of 1.1 9 109/L (reference range
0.8 9 109/L), troponin of 1.7 lg/L (reference range
\0.4 lg/L) and C-reactive protein of 32 mg/L (reference
range\5.0 mg/L). Electrocardiography showed clockwise
rotation without changes in the ST/T segment. Echocar-
diography revealed normal systolic function of the non-
dilated left ventricle, a diastolic dysfunction of the first
degree, and a slightly diffused and thickened myocardium
with minimal pericardial effusion of up to 4 mm behind the
posterior wall of the left ventricle. The possibility of initial
right pneumonia was described on the chest radiography,
without auscultatory findings confirming the diagnosis.
Arterial blood gas analysis determined an adequate respi-
ratory function with normal pH and gas levels. Despite the
uncertainty of the diagnosis of pneumonia, empiric therapy
including amoxicillin/clavulanic acid (1000/200 mg three
times daily) and azithromycin (500 mg once daily) was
administered. Ibuprofen (600 mg three times daily) was
also administered due to the pericardial effusion. After
5 days of hospitalisation, the patient’s symptoms did not
improve. Moreover, the patient was feeling even sicker,
had chills, intensive muscular pain and a cough. His new
laboratory tests revealed a leukocyte count of 19.2 9 109/L
and an eosinophil count of 11.2 9 109/L (Fig. 1). Troponin
levels rose to 4 lg/L. Echocardiography showed no dif-
ference as compared with the patient’s first check-up. Pulse
doses of corticosteroids (methylprednisolone 500 mg
intravenously) were administered and all other therapy was
discontinued. The patient felt relief 7 h later. A fall in the
absolute leukocyte and eosinophil counts was observed
(leukocytes 9 9 109/L; eosinophils 1.32 9 109/L). No
heart rhythm disturbance or heart failure symptoms were
noted. Therapy with pulse doses of methylprednisolone
(500 mg intravenously for each dose) was continued for up
to 3 days, after which it was changed to oral methylpred-
nisolone therapy (initially methylprednisolone 64 mg,
which was decreased every week for 2 months). Coronary
angiography showed two-vessel disease with significant
stenosis of the circumflex and right coronary artery. In the
same procedure, percutaneous coronary intervention was
performed with the implantation of one stent in the cir-
cumflex artery (Fig. 2). Endomyocardial biopsy was also
performed, which showed no inflammation. Ramipril was
initiated as a new antihypertensive therapy and dual
Fig. 1 Leukocyte and absolute
eosinophil count chart
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antiplatelet therapy with acetylsalicylic acid and clopido-
grel was prolonged.
A second percutaneous coronary intervention was per-
formed 3 weeks later with the implantation of one stent in
the right coronary artery (Fig. 3). The clinical status
showed no abnormalities. The echocardiography per-
formed showed regular systolic function of both ventricles
and that the wall thickness was of the same size as in the
first check-up, but without pericardial effusion. The patient
was asymptomatic and a complete blood count was normal
with normal levels of leukocytes and eosinophils.
Discussion
EM has high morbidity and mortality rates and early
administration of systemic corticosteroids is necessary
regardless of the underlying causes because delayed treat-
ment may result in fatal outcomes [4].
The diagnostic criteria proposed by the Japanese Cir-
culation Society Task Force can be very useful in the early
recognition of EM. Their criteria include three subgroups:
required clinical condition (blood eosinophilia[0.5 9 109/
L, cardiac symptoms, elevated cardiac enzymes, ECG
changes and abnormal echocardiography in the setting of
unremarkable coronary angiography); useful information
(previous allergy manifestations and flu-like symptoms);
and endomyocardial biopsy findings [5]. According to
these guidelines, our patient fulfilled enough criteria
required for strong suspicion of EM. There were no ECG
changes, but as proposed in these guidelines, electrocar-
diographic changes do not have to be present in 50 % of
patients. Respiratory-dependent chest pain with flu-like
symptoms and laboratory findings suggested inflammation
as a general mechanism of the disease. Echocardiography
findings of a thickened wall and pericardial effusion were
in favour of myopericarditis. According to the literature, a
few case reports of EM have been described with an
absolute eosinophil count of 3.5 9 109/L, but our patient
had much higher levels (11.2 9 109/L) [6]. Endomyocar-
dial biopsy revealed no myocardial inflammation, but it
was performed on the third day after a pulse dosage of
intravenous corticosteroids when the symptoms had com-
pletely disappeared. Also, it should be noted that EM is
Fig. 2 Significant coronary
stenosis of the circumflex artery
before percutaneous coronary




Fig. 3 Significant coronary
stenosis of the right coronary
artery before percutaneous
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usually a localised inflammatory disease, so bioptic mate-
rial is not needed to prove the diagnosis as the sample does
not have to be taken from inflamed tissue.
There are different types of EM. One of the most
common causes described is a hypersensitivity to various
drugs, usually antibiotics, anticonvulsants and diuretics. It
is possible, but uncommon, that the appearance of drug-
induced EM can be delayed for up to 2 years [3, 4]. The
fact that drugs that cause one type of idiosyncratic drug
reaction with allergic features often cause other types of
similar idiosyncratic reactions only causes more doubt
regarding the possible aetiology. A high incidence of such
idiosyncratic drug reactions is not known to appear with
hydrochlorothiazide and there are only a few case reports
describing the potential cause of hydrochlorothiazide-in-
duced EM in the literature, which highlights the difficulty
of establishing a causal relationship [4, 6]. No connections
between budesonide/formoterol and EM were found. In a
clinical sense, it is unlikely that antibiotics could have
caused EM in this case as the symptoms characterising EM
were present before these agents were administrated.
Therefore, because the causality assessment is difficult, it is
unclear if this myocarditis was drug induced or if it may be
idiopathic as well.
It is more obvious that coronary artery disease was a co-
finding in this case, because the symptoms of acute coro-
nary syndrome cannot be resolved using corticosteroids,
and troponin levels would not decrease on the second day
after the therapy was initiated. Trends in leukocyte and
absolute eosinophil count support this hypothesis.
Conclusion
It should be emphasised that proper initial diagnosis of EM
and early treatment with pulse doses of intravenous corti-
costeroid therapy should not be delayed, because untreated
myocarditis could result in heart failure and death [7, 8].
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